• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去乙酰化酶抑制剂在携带激活型kRasV12的细胞中选择性地诱导细胞死亡:信号转导子和转录激活子1及p21的作用

Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.

作者信息

Klampfer Lidija, Huang Jie, Shirasawa Senji, Sasazuki Takehiko, Augenlicht Leonard

机构信息

Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York 10467, USA.

出版信息

Cancer Res. 2007 Sep 15;67(18):8477-85. doi: 10.1158/0008-5472.CAN-07-0210.

DOI:10.1158/0008-5472.CAN-07-0210
PMID:17875686
Abstract

Histone deacetylase (HDAC) inhibitors (HDACi) show potent and selective antitumor activity despite the fact that they induce histone hyperacetylation in both normal and tumor cells. In this study, we showed that the inducible expression of kRasV12 in nontransformed intestinal epithelial cells significantly lowered the mitochondrial membrane potential (MMP) and sensitized cells to HDACi-induced apoptosis. Consistent with our finding that colon cancer cell lines with mutant Ras have reduced expression of signal transducers and activators of transcription 1 (STAT1), we showed that inducible expression of mutant Ras markedly decreased both basal and inducible expression of STAT1, a transcription factor with tumor suppressor activity. To investigate whether reduced expression of STAT1 in cells that harbor mutant Ras contributes to their increased sensitivity to HDACi, we silenced the expression of STAT1 in HKe-3 cells with small interfering RNA. Despite the fact that silencing of STAT1 was not sufficient to alter the MMP, STAT1 deficiency, like Ras mutations, sensitized cells to apoptosis induced by HDACi. We showed that the induction of p21 by HDACi was significantly impaired in HKe-3 cells with silenced STAT1 expression and showed that the ability of butyrate to activate p21 transcription was diminished in STAT1-deficient HKe-3 cells. Finally, we used cells with targeted deletion of p21 to confirm that p21 protects cells from butyrate-induced apoptosis, strongly suggesting that in these cells STAT1 deficiency promotes butyrate-induced apoptosis through impaired induction of p21. Our data therefore establish that Ras mutations, and consequent reduction in the expression of STAT1, underlie the increased susceptibility of transformed cells to undergo apoptosis in response to treatment with inhibitors of HDAC activity.

摘要

组蛋白去乙酰化酶(HDAC)抑制剂(HDACi)表现出强大且具有选择性的抗肿瘤活性,尽管它们会在正常细胞和肿瘤细胞中均诱导组蛋白过度乙酰化。在本研究中,我们发现非转化的肠上皮细胞中可诱导的kRasV12表达显著降低了线粒体膜电位(MMP),并使细胞对HDACi诱导的凋亡敏感。与我们发现具有突变Ras的结肠癌细胞系中信号转导子和转录激活子1(STAT1)表达降低一致,我们表明突变Ras的可诱导表达显著降低了具有肿瘤抑制活性的转录因子STAT1的基础表达和诱导表达。为了研究携带突变Ras的细胞中STAT1表达降低是否导致它们对HDACi的敏感性增加,我们用小干扰RNA使HKe - 3细胞中STAT1的表达沉默。尽管沉默STAT1不足以改变MMP,但与Ras突变一样,STAT1缺陷使细胞对HDACi诱导的凋亡敏感。我们发现,在STAT1表达沉默的HKe - 3细胞中,HDACi对p21的诱导显著受损,并且表明在STAT1缺陷的HKe - 3细胞中丁酸激活p21转录的能力减弱。最后,我们使用p21靶向缺失的细胞来证实p21保护细胞免受丁酸诱导的凋亡,强烈表明在这些细胞中STAT1缺陷通过受损的p21诱导促进丁酸诱导的凋亡。因此,我们的数据证实Ras突变以及随之而来的STAT1表达降低是转化细胞对HDAC活性抑制剂治疗反应中凋亡易感性增加的基础。

相似文献

1
Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.组蛋白去乙酰化酶抑制剂在携带激活型kRasV12的细胞中选择性地诱导细胞死亡:信号转导子和转录激活子1及p21的作用
Cancer Res. 2007 Sep 15;67(18):8477-85. doi: 10.1158/0008-5472.CAN-07-0210.
2
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.组蛋白去乙酰化酶2(HDAC2)缺陷通过抑制核因子κB(NF-κB)活性使结肠癌细胞对肿瘤坏死因子α(TNFα)诱导的凋亡敏感。
Exp Cell Res. 2008 Apr 15;314(7):1507-18. doi: 10.1016/j.yexcr.2008.01.010. Epub 2008 Jan 19.
3
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.组蛋白去乙酰化酶抑制剂通过依赖p21Cip1的survivin水平降低增强来沙妥珠单抗诱导的细胞凋亡。
Cancer Res. 2007 Jul 15;67(14):6987-94. doi: 10.1158/0008-5472.CAN-07-0812.
4
Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.在鳞状细胞癌发生过程中,启动子甲基化导致STAT1表达降低。
J Natl Cancer Inst. 2006 Feb 1;98(3):181-9. doi: 10.1093/jnci/djj020.
5
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.在缺乏p21Waf的情况下,组蛋白去乙酰化酶抑制剂诱导的高效结肠癌细胞凋亡需要视网膜母细胞瘤蛋白。
Biochem Pharmacol. 2005 Apr 1;69(7):1059-67. doi: 10.1016/j.bcp.2004.12.017.
6
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.p53和p21对HDAC抑制剂介导的HCT116结肠癌细胞体外和体内凋亡的差异反应。
Int J Oncol. 2007 Dec;31(6):1391-402.
7
Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.组蛋白脱乙酰酶抑制剂曲古抑菌素A对H-ras转化的乳腺上皮细胞凋亡调控的影响。
Int J Mol Med. 2008 Nov;22(5):605-11.
8
Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.组蛋白脱乙酰酶抑制剂阿皮西丁对H-ras转化的乳腺上皮细胞凋亡调控的影响。
Int J Mol Med. 2008 Mar;21(3):325-33.
9
STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.STAT1 通过抑制 Skp2 基因转录促进 Ras 转化细胞中 p27Kip1 的稳定。
Mol Cancer Res. 2010 May;8(5):798-805. doi: 10.1158/1541-7786.MCR-10-0027. Epub 2010 Apr 20.
10
Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.甲基化CpG结合域蛋白3通过组蛋白去乙酰化酶抑制剂在肺癌细胞中通过差异转录重编程介导癌症选择性细胞毒性。
Cancer Res. 2005 Dec 15;65(24):11400-10. doi: 10.1158/0008-5472.CAN-05-1092.

引用本文的文献

1
KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.KRAS 突变与共识分子亚型 2 和 3 独立与结直肠癌免疫浸润和反应性降低相关。
Clin Cancer Res. 2018 Jan 1;24(1):224-233. doi: 10.1158/1078-0432.CCR-17-1090. Epub 2017 Oct 23.
2
Protein kinase D signaling in cancer: A friend or foe?蛋白激酶 D 信号通路与癌症:是敌是友?
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):283-294. doi: 10.1016/j.bbcan.2017.05.008. Epub 2017 May 31.
3
The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells.
STAT1 在成纤维细胞与结肠癌细胞串扰中的作用。
Front Oncol. 2014 Apr 30;4:88. doi: 10.3389/fonc.2014.00088. eCollection 2014.
4
Malignant peripheral nerve sheath tumors.恶性外周神经鞘瘤。
Oncologist. 2014 Feb;19(2):193-201. doi: 10.1634/theoncologist.2013-0328. Epub 2014 Jan 27.
5
Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.耐阿皮西丁的HA22T肝癌细胞通过激活IGF-IR/PI3K/Akt信号通路大量促进细胞存活能力。
Tumour Biol. 2014 Jan;35(1):303-13. doi: 10.1007/s13277-013-1041-3. Epub 2013 Aug 30.
6
Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.组蛋白去乙酰化酶抑制剂通过阻断 PKC 诱导的 IGFBP-3 降解增强胰岛素样生长因子结合蛋白-3 的凋亡活性。
Int J Cancer. 2012 Nov 15;131(10):2253-63. doi: 10.1002/ijc.27509. Epub 2012 Mar 28.
7
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.AR42,一种新型组蛋白去乙酰化酶抑制剂,有望成为治疗听神经瘤和脑膜瘤的潜在方法。
Neuro Oncol. 2011 Sep;13(9):983-99. doi: 10.1093/neuonc/nor072. Epub 2011 Jul 21.
8
Deacetylase inhibitors - focus on non-histone targets and effects.脱乙酰酶抑制剂——聚焦于非组蛋白靶点及效应。
World J Biol Chem. 2010 May 26;1(5):55-61. doi: 10.4331/wjbc.v1.i5.55.
9
STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction.STAT6 激活在溃疡性结肠炎中的作用:预防 IL-13 诱导的结肠上皮细胞功能障碍的新靶点。
Inflamm Bowel Dis. 2011 Nov;17(11):2224-34. doi: 10.1002/ibd.21628. Epub 2011 Feb 9.
10
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.自噬在抵抗组蛋白去乙酰化酶抑制剂中的存活:治疗恶性外周神经鞘瘤的新策略。
Cancer Res. 2011 Jan 1;71(1):185-96. doi: 10.1158/0008-5472.CAN-10-2799. Epub 2010 Nov 16.